PD-11.11 von van der Heijden, A.G., Hendricksen, K., Cornel, E.B., Vergunst, H., de Reijke, T.M., van Boven, E., Barten, E.J., Chawla, S., Lenaz, G., Witjes, J.A.

Volltext

PD-11.11: Phase II marker lesion study with intravesical instillation of Eoquin ™ in superficial bladder cancer: toxicity, marker response and follow up von van der Heijden, A.G., Hendricksen, K., Cornel, E.B., Vergunst, H., de Reijke, T.M., van Boven, E., Barten, E.J., Chawla, S., Lenaz, G., Witjes, J.A.

Volltext

PHASE II MARKER LESION STUDY WITH INTRAVESICAL INSTILLATION OF EOQUIN TM IN SUPERFICIAL BLADDER CANCER, TOXICITY AND MARKER RESPONSE - THE FINAL RESULTS von Van der Heijden, A.G., Moonen, P.M.J., Cornel, E.B., Vergunst, H., De Reijke, T.M., Van Boven, E., Barten, E.J., Puri, R., Chawla, S., Lenaz, G., Witjes, J.A.

Volltext

Iliopsoas abscess associated with endovascular infection: an acute case of chronic Q fever von Barten, Dennis G., MD, Gulikers, Donné E.J., MD, Versteegen, Marieke G.J., MD, Thimister, Willie P.W.L., MD, PhD, de Mast, Quirijn, MD, PhD, Bleeker-Rovers, Chantal P., MD, PhD

Volltext

VX-497 inhibits IMPDH and is the first rationally synthesized immunosuppressant to prolong allograft survival von Gummert, J.F., Barten, M.J., Boeke, K., Leon, E.J., Decker, C.J., Nimmesgem, E., Billingham, M.E., Morris, R.E.

Volltext